CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


NiclosamideWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (10)


Name (Synonyms) Correlation
drug1708 Other drugs Wiki 0.71
drug1100 Hydroxychloroquine Oral Product Wiki 0.71
drug2456 Telehealth monitoring Wiki 0.71
drug2004 RO6953958 Wiki 0.71
drug1090 Hydroxychloroquine + azithromycin Wiki 0.50
drug560 Chloroquine Wiki 0.25
drug1598 Nitazoxanide Wiki 0.25
drug923 Favipiravir Wiki 0.17
drug1270 Ivermectin Wiki 0.17
drug1822 Placebo Wiki 0.08

Correlated MeSH Terms (10)


Name (Synonyms) Correlation
D002658 Developmental Disabilities NIH 0.71
D065886 Neurodevelopmental Disorders NIH 0.50
D002659 Child Development Disorders, Pervasive NIH 0.41
D001321 Autistic Disorder NIH 0.35
D000067877 Autism Spectrum Disorder NIH 0.29
D001523 Mental Disorders NIH 0.15
D004194 Disease NIH 0.13
D007239 Infection NIH 0.04
D045169 Severe Acute Respiratory Syndrome NIH 0.04
D018352 Coronavirus Infections NIH 0.03

Correlated HPO Terms (2)


Name (Synonyms) Correlation
HP:0000717 Autism HPO 0.35
HP:0000729 Autistic behavior HPO 0.29

There are 2 clinical trials

Clinical Trials


1 The Results of COVID 19 Treatment: A Real-life Experience on Patients With COVID 19

COVID 19 treatment using Chloroquine with or without Azithromycin, Faviprevir, Nitazoxanide, Ivermectin.

NCT04345419 COVID Drug: Chloroquine Drug: Favipiravir Drug: Nitazoxanide Drug: Ivermectin Drug: Niclosamide Drug: Other drugs

Primary Outcomes

Description: the estimated number of patients with decreased viral load

Measure: Number of patients with decreased viral load

Time: 6 months

2 Niclosamide for Patients With Mild to Moderate Disease From Novel Coronavirus (COVID-19)

This study will evaluate the antihelmintic drug, Niclosamide, as a potential treatment for mild to moderate coronavirus disease 2019 (COVID-19).

NCT04399356 COVID (SARS-CoV-2) Drug: Niclosamide Drug: Placebo Other: Telehealth monitoring

Primary Outcomes

Description: Oropharangeal swab

Measure: Change in respiratory viral clearance (by PCR)

Time: Day 3 and 10

Secondary Outcomes

Description: Fecal swab

Measure: Fecal viral clearance (by PCR)

Time: Day 14

Description: Oropharngeal swab

Measure: Reduction (change) in viral shedding (by PCR)

Time: Days 1,3,7,10,14


No related HPO nodes (Using clinical trials)